{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T22:31:19Z","timestamp":1791844279851,"version":"4.3.4"},"reference-count":179,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400846"],"award-info":[{"award-number":["82400846"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2024-NHLHCRF-JBGS-WZ-03"],"award-info":[{"award-number":["2024-NHLHCRF-JBGS-WZ-03"]}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"publisher","award":["7244407"],"award-info":[{"award-number":["7244407"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.ebiom.2025.105785","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T04:58:17Z","timestamp":1748926697000},"page":"105785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Advances in precision medicine for lupus nephritis: biomarker- and AI-driven diagnosis and treatment response prediction and targeted therapies"],"prefix":"10.1016","volume":"117","author":[{"given":"Shunlai","family":"Shang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jikai","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosen","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinggang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangmei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ebiom.2025.105785_bib1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1001\/jama.2024.2315","article-title":"Systemic lupus erythematosus: a review","volume":"331","author":"Siegel","year":"2024","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","article-title":"Lupus nephritis","volume":"6","author":"Anders","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/BOR.0000000000000887","article-title":"Pathogenesis of lupus nephritis: the contribution of immune and kidney resident cells","volume":"35","author":"Bhargava","year":"2023","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib4","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41584-024-01158-w","article-title":"Lupus nephritis-related chronic kidney disease","volume":"20","author":"Lichtnekert","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib5","doi-asserted-by":"crossref","first-page":"A277","DOI":"10.1016\/j.autrev.2009.12.008","article-title":"The geoepidemiology of systemic lupus erythematosus","volume":"9","author":"Borchers","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib6","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.cell.2021.01.015","article-title":"Precision medicine in 2030\u2014seven ways to transform healthcare","volume":"184","author":"Denny","year":"2021","journal-title":"Cell"},{"issue":"6586","key":"10.1016\/j.ebiom.2025.105785_bib7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1126\/science.abj5117","article-title":"Multiple causal variants underlie genetic associations in humans","volume":"375","author":"Abell","year":"2022","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s42255-023-00753-7","article-title":"Proteogenomic links to human metabolic diseases","volume":"5","author":"Koprulu","year":"2023","journal-title":"Nat Metab"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.kint.2023.08.025","article-title":"A novel multi-ancestry proteome-wide Mendelian randomization study implicates extracellular proteins, tubular cells, and fibroblasts in estimated glomerular filtration rate regulation","volume":"104","author":"Lanktree","year":"2023","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1172\/JCI126120","article-title":"Precision medicine: discovering clinically relevant and mechanistically anchored disease subgroups at scale","volume":"129","author":"Rosen","year":"2019","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25020805","article-title":"Lupus nephritis biomarkers: a critical review","volume":"25","author":"Alduraibi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/annrheumdis-2019-216227","article-title":"High genetic risk score is associated with early disease onset, damage accrual and decreased survival in systemic lupus erythematosus","volume":"79","author":"Reid","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib13","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1136\/ard-2023-223880","article-title":"Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy","volume":"82","author":"Kostopoulou","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib14","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1038\/s41590-019-0398-x","article-title":"The immune cell landscape in kidneys of patients with lupus nephritis","volume":"20","author":"Arazi","year":"2019","journal-title":"Nat Immunol"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib15","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1093\/rheumatology\/keaa767","article-title":"Serum IgG2 antibody multicomposition in systemic lupus erythematosus and lupus nephritis (Part 1): cross-sectional analysis","volume":"60","author":"Bruschi","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib16","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2019121285","article-title":"Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis","volume":"31","author":"Mejia-Vilet","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib17","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/j.kint.2016.08.010","article-title":"Serum A08 C1q antibodies are associated with disease activity and prognosis in Chinese patients with lupus nephritis","volume":"90","author":"Pang","year":"2016","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.03990415","article-title":"Relationship of circulating anti-C3b and anti-C1q IgG to lupus nephritis and its flare","volume":"11","author":"Birmingham","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0961203319828822","article-title":"Anti-\u03b1-enolase antibody combined with \u03b22 microglobulin evaluated the incidence of nephritis in systemic lupus erythematosus patients","volume":"28","author":"Huang","year":"2019","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib20","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3899\/jrheum.191094","article-title":"Risk of renal failure within 10 or 20 years of systemic lupus erythematosus diagnosis","volume":"48","author":"Petri","year":"2021","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib21","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1177\/0961203318770006","article-title":"Urinary cytokines and mRNA expression as biomarkers of disease activity in lupus nephritis","volume":"27","author":"Jakiela","year":"2018","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s13075-020-02209-9","article-title":"Urinary activated leukocyte cell adhesion molecule as a novel biomarker of lupus nephritis histology","volume":"22","author":"Ding","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ebiom.2025.105785_bib23","article-title":"Elevated serum levels of human epididymis protein 4 in adult patients with proliferative lupus nephritis","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105785_bib24","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.intimp.2018.04.048","article-title":"Serum human epididymis protein 4 is a predictor for developing nephritis in patients with systemic lupus erythematosus: a prospective cohort study","volume":"60","author":"Ren","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib25","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/03009742.2016.1231339","article-title":"Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis","volume":"46","author":"Parodis","year":"2017","journal-title":"Scand J Rheumatol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-50231-y","article-title":"SLE plasma profiling identifies unique signatures of lupus nephritis and discoid","volume":"9","author":"Smith","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1677","article-title":"Serum exosomal tsRNA biomarkers: a novel strategy for identifying lupus nephritis","volume":"14","author":"Yang","year":"2024","journal-title":"Clin Transl Med"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib28","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1177\/0961203319842663","article-title":"Combination immunosuppressant therapy and lupus nephritis outcome: a hospital-based study","volume":"28","author":"Chen","year":"2019","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.12743","article-title":"Insulin-like growth factor binding protein-2 as a novel biomarker for disease activity and renal pathology changes in lupus nephritis","volume":"184","author":"Ding","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ebiom.2025.105785_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1326836","article-title":"Circulating exosomal microRNAs as biomarkers of lupus nephritis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.830","article-title":"Serum tsRNA as a novel molecular diagnostic biomarker for lupus nephritis","volume":"12","author":"Zhang","year":"2022","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.ebiom.2025.105785_bib32","article-title":"A novel serum tsRNA for diagnosis and prediction of nephritis in SLE","volume":"12","author":"Yang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105785_bib33","article-title":"Discovery of novel circulating immune complexes in lupus nephritis using immunoproteomics","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224707","article-title":"Elevated interleukin-25 and its association to Th2 cytokines in systemic lupus erythematosus with lupus nephritis","volume":"14","author":"Selvaraja","year":"2019","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib35","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1021\/acs.jproteome.5b00905","article-title":"Antibody-array-based proteomic screening of serum markers in systemic lupus erythematosus: a discovery study","volume":"15","author":"Wu","year":"2016","journal-title":"J Proteome Res"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib36","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1177\/0961203320979042","article-title":"Serum uric acid as a predictor for nephritis in Egyptian patients with systemic lupus erythematosus","volume":"30","author":"Hafez","year":"2021","journal-title":"Lupus"},{"issue":"20","key":"10.1016\/j.ebiom.2025.105785_bib37","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.7150\/thno.63743","article-title":"BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus","volume":"11","author":"Chuang","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib38","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13075-017-1498-3","article-title":"Urinary angiostatin, CXCL4 and VCAM-1 as biomarkers of lupus nephritis","volume":"20","author":"Mok","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000763","article-title":"Urine proteomic insights from the belimumab in lupus nephritis trial","volume":"9","author":"Weeding","year":"2022","journal-title":"Lupus Sci Med"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib40","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1093\/rheumatology\/keaa851","article-title":"A panel of urinary proteins predicts active lupus nephritis and response to rituximab treatment","volume":"60","author":"Davies","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0961203320914372","article-title":"Diagnostic value of urinary monocyte chemoattractant protein-1 in evaluating the activity of lupus nephritis: a meta-analysis","volume":"29","author":"Xia","year":"2020","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0240942","article-title":"The utility of urinary biomarker panel in predicting renal pathology and treatment response in Chinese lupus nephritis patients","volume":"15","author":"Liu","year":"2020","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib43","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s10067-020-05454-0","article-title":"Urinary levels of ceruloplasmin and monocyte chemoattractant protein-1 correlate with extra-capillary proliferation and chronic damage in patients with lupus nephritis","volume":"40","author":"Urrego-Callejas","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib44","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar3912","article-title":"Urine VCAM-1 as a marker of renal pathology activity index in lupus nephritis","volume":"14","author":"Singh","year":"2012","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105785_bib45","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/ndt\/gfw214","article-title":"Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis","volume":"31","author":"Endo","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib46","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s41927-020-00162-3","article-title":"Urinary soluble VCAM-1 is a useful biomarker of disease activity and treatment response in lupus nephritis","volume":"4","author":"Gasparin","year":"2020","journal-title":"BMC Rheumatol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib47","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1038\/s41467-020-15986-3","article-title":"Comprehensive aptamer-based screening identifies a spectrum of urinary biomarkers of lupus nephritis across ethnicities","volume":"11","author":"Stanley","year":"2020","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105785_bib48","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1093\/rheumatology\/kez528","article-title":"ALCAM and VCAM-1 as urine biomarkers of activity and long-term renal outcome in systemic lupus erythematosus","volume":"59","author":"Parodis","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib49","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/14789450.2020.1874356","article-title":"Targeted urine proteomics in lupus nephritis \u2013 a meta-analysis","volume":"17","author":"Zhang","year":"2020","journal-title":"Expert Rev Proteomics"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib50","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210633","article-title":"BKV microRNA, and urinary neutrophil gelatinase-associated lipocalin can be used as potential biomarkers of lupus nephritis","volume":"14","author":"Li","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib51","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1177\/0961203317738226","article-title":"Urinary neutrophil gelatinase-associated lipocalin and monocyte chemoattractant protein 1 as biomarkers for lupus nephritis in Colombian SLE patients","volume":"27","author":"G\u00f3mez-Puerta","year":"2018","journal-title":"Lupus"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib52","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.34426","article-title":"Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis","volume":"64","author":"Brunner","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105785_bib53","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1093\/ndt\/gfu062","article-title":"Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis","volume":"29","author":"Torres-Salido","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ebiom.2025.105785_bib54","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/2768326","article-title":"Elevated urinary neutrophil gelatinase-associated lipocalin is a biomarker for lupus nephritis: a systematic review and meta-analysis","volume":"2020","author":"Gao","year":"2020","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib55","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s13075-019-1959-y","article-title":"Urinary pro-thrombotic, anti-thrombotic, and fibrinolytic molecules as biomarkers of lupus nephritis","volume":"21","author":"Qin","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.reuma.2018.02.002","article-title":"Utility of urinary transferrin and ceruloplasmin in patients with systemic lupus erythematosus for differentiating patients with lupus nephritis","volume":"16","author":"Urrego","year":"2020","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"13","key":"10.1016\/j.ebiom.2025.105785_bib57","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1177\/0961203318804885","article-title":"Urinary B-cell-activating factor of the tumour necrosis factor family (BAFF) in systemic lupus erythematosus","volume":"27","author":"Vincent","year":"2018","journal-title":"Lupus"},{"key":"10.1016\/j.ebiom.2025.105785_bib58","article-title":"Urinary exosome tsRNAs as novel markers for diagnosis and prediction of lupus nephritis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.638","article-title":"Discovery of urine biomarkers for lupus nephritis via quantitative and comparative proteome analysis","volume":"11","author":"Kwon","year":"2021","journal-title":"Clin Transl Med"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib60","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.42941","article-title":"Association of autoantibody concentrations and trajectories with lupus nephritis histologic features and treatment response","volume":"76","author":"Fava","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.ebiom.2025.105785_bib61","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1471-2369-14-63","article-title":"Serum levels and renal deposition of C1q complement component and its antibodies reflect disease activity of lupus nephritis","volume":"14","author":"Tan","year":"2013","journal-title":"BMC Nephrol"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib62","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1177\/09612033211004727","article-title":"Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis","volume":"30","author":"Yu","year":"2021","journal-title":"Lupus"},{"key":"10.1016\/j.ebiom.2025.105785_bib63","article-title":"Anti-DFS70 antibodies are associated with proliferative lupus nephritis and renal pathological activity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.105785_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103165","article-title":"Proximity extension assay proteomics and renal single cell transcriptomics uncover novel urinary biomarkers for active lupus nephritis","volume":"143","author":"Li","year":"2024","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib65","article-title":"Serum antineutrophil cytoplasmic antibody positivity at the time of renal biopsy is associated with disease activity of lupus nephritis","volume":"46","author":"Zhang","year":"2024","journal-title":"Ren Fail"},{"key":"10.1016\/j.ebiom.2025.105785_bib66","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s13075-015-0879-8","article-title":"Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up","volume":"17","author":"Pesickova","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/0961203315598018","article-title":"Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis","volume":"25","author":"Yap","year":"2016","journal-title":"Lupus"},{"key":"10.1016\/j.ebiom.2025.105785_bib68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.imlet.2019.04.002","article-title":"Analysis of interleukin-17 and interleukin-23 for estimating disease activity and predicting the response to treatment in active lupus nephritis patients","volume":"210","author":"Dedong","year":"2019","journal-title":"Immunol Lett"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib69","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001038","article-title":"Circulating neutrophil extracellular trap remnants as a biomarker to predict outcomes in lupus nephritis","volume":"11","author":"Whittall-Garcia","year":"2024","journal-title":"Lupus Sci Med"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib70","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1136\/annrheumdis-2019-216312","article-title":"Quantitative planar array screen of 1000 proteins uncovers novel urinary protein biomarkers of lupus nephritis","volume":"79","author":"Vanarsa","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib71","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/art.42023","article-title":"Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis","volume":"74","author":"Fava","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.172569","article-title":"Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis","volume":"9","author":"Fava","year":"2024","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib73","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.kint.2024.09.007","article-title":"Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts","volume":"106","author":"Vodehnal","year":"2024","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib74","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147334","article-title":"The CD6\/ALCAM pathway promotes lupus nephritis via T cell-mediated responses","volume":"132","author":"Chalmers","year":"2022","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib75","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1093\/rheumatology\/keae559","article-title":"Soluble urine activated leukocyte cell adhesion molecule is a strong predictor of lupus nephritis","volume":"64","author":"Chu","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"26","key":"10.1016\/j.ebiom.2025.105785_bib76","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011287","article-title":"Rapid detection of urinary soluble intercellular adhesion molecule-1 for determination of lupus nephritis activity","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"key":"10.1016\/j.ebiom.2025.105785_bib77","article-title":"Association of urine sCD163 with proliferative lupus nephritis, fibrinoid necrosis, cellular crescents and intrarenal M2 macrophages","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib78","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/art.40813","article-title":"Identification of low-abundance urinary biomarkers in lupus nephritis using electrochemiluminescence immunoassays","volume":"71","author":"Stanley","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib79","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1177\/0961203318778774","article-title":"Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare","volume":"27","author":"Go","year":"2018","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000569","article-title":"Discovery of NEU1 as a candidate renal biomarker for proliferative lupus nephritis chronicity","volume":"8","author":"Mao","year":"2021","journal-title":"Lupus Sci Med"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib81","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.kint.2017.04.029","article-title":"Positive antineutrophil cytoplasmic antibody serology in patients with lupus nephritis is associated with distinct histopathologic features on renal biopsy","volume":"92","author":"Turner-Stokes","year":"2017","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib82","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1681\/ASN.2013121356","article-title":"Colony-stimulating factor-1: a potential biomarker for lupus nephritis","volume":"26","author":"Menke","year":"2015","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib83","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001257","article-title":"Urine and serum S100A8\/A9 and S100A12 associate with active lupus nephritis and may predict response to rituximab treatment","volume":"6","author":"Davies","year":"2020","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib84","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1002\/art.39623","article-title":"Development of biomarker models to predict outcomes in lupus nephritis","volume":"68","author":"Wolf","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib85","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/1756-185X.12433","article-title":"Human neutrophil peptide 1-3, a component of the neutrophil extracellular trap, as a potential biomarker of lupus nephritis","volume":"18","author":"Cheng","year":"2015","journal-title":"Int J Rheum Dis"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib86","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2024-001347","article-title":"Interferon-\u03b1 as a biomarker to predict renal outcomes in lupus nephritis","volume":"11","author":"Whittall Garcia","year":"2024","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ebiom.2025.105785_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103073","article-title":"Extracellular vesicles opsonized by monomeric C-reactive protein (CRP) are accessible as autoantigens in patients with systemic lupus erythematosus and associate with autoantibodies against CRP","volume":"139","author":"Karlsson","year":"2023","journal-title":"J Autoimmun"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib88","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/art.41507","article-title":"Association between urinary epidermal growth factor and renal prognosis in lupus nephritis","volume":"73","author":"Mejia-Vilet","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"18","key":"10.1016\/j.ebiom.2025.105785_bib89","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184601","article-title":"Urinary neuropilin-1: a predictive biomarker for renal outcome in lupus nephritis","volume":"20","author":"Torres-Salido","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1S","key":"10.1016\/j.ebiom.2025.105785_bib90","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","article-title":"KDIGO 2024 clinical practice guideline for the management of LUPUS NEPHRITIS","volume":"105","author":"Rovin","year":"2024","journal-title":"Kidney Int"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib91","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","article-title":"Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways","volume":"20","author":"Der","year":"2019","journal-title":"Nat Immunol"},{"key":"10.1016\/j.ebiom.2025.105785_bib92","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cca.2021.12.029","article-title":"Laboratory evaluation of anti-dsDNA antibodies","volume":"528","author":"Cockx","year":"2022","journal-title":"Clin Chim Acta"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib93","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0272-6386(99)70082-X","article-title":"Clinical and prognostic value of serial renal biopsies in lupus nephritis","volume":"34","author":"Moroni","year":"1999","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000689","article-title":"Clinical and histological findings at second but not at first kidney biopsy predict end-stage kidney disease in a large multicentric cohort of patients with active lupus nephritis","volume":"9","author":"Gatto","year":"2022","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.ebiom.2025.105785_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104427","article-title":"Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decade","volume":"88","author":"Berb\u00eds","year":"2023","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib96","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1021\/acs.jproteome.2c00768","article-title":"Rapid molecular evaluation of human kidney tissue sections by in situ mass spectrometry and machine learning to classify the nephrotic syndrome","volume":"22","author":"Mondal","year":"2023","journal-title":"J Proteome Res"},{"key":"10.1016\/j.ebiom.2025.105785_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.105179","article-title":"An efficient multilevel thresholding image segmentation method based on the slime mould algorithm with bee foraging mechanism: a real case with lupus nephritis images","volume":"142","author":"Chen","year":"2022","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.ebiom.2025.105785_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2023.106950","article-title":"A grade-based search adaptive random slime mould optimizer for lupus nephritis image segmentation","volume":"160","author":"Shi","year":"2023","journal-title":"Comput Biol Med"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib99","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.kint.2024.12.007","article-title":"Multi-stain deep learning prediction model of treatment response in lupus nephritis based on renal histopathology","volume":"107","author":"Cheng","year":"2025","journal-title":"Kidney Int"},{"key":"10.1016\/j.ebiom.2025.105785_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.artmed.2024.103042","article-title":"Rough hypervolume-driven feature selection with groupwise intelligent sampling for detecting clinical characterization of lupus nephritis","volume":"160","author":"Zhou","year":"2025","journal-title":"Artif Intell Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103422","article-title":"Is per-protocol kidney biopsy required in lupus nephritis?","volume":"23","author":"Parodis","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib102","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1093\/ndt\/gfad191","article-title":"A nomogram predicting the histologic activity of lupus nephritis from clinical parameters","volume":"39","author":"Gao","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ebiom.2025.105785_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105435","article-title":"Lupus nephritis diagnosis using enhanced moth flame algorithm with support vector machines","volume":"145","author":"Wang","year":"2022","journal-title":"Comput Biol Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib104","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-071821","article-title":"Deep learning model to predict lupus nephritis renal flare based on dynamic multivariable time-series data","volume":"14","author":"Huang","year":"2024","journal-title":"BMJ Open"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib105","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1136\/annrheumdis-2021-222069","article-title":"Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis","volume":"81","author":"Frangou","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib106","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/ard-2022-223808","article-title":"Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes","volume":"82","author":"Choi","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib107","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1093\/ndt\/gfw068","article-title":"Con: cyclophosphamide for the treatment of lupus nephritis","volume":"31","author":"Mok","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib108","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.autrev.2018.04.007","article-title":"Does cyclophosphamide still play a role in glomerular diseases?","volume":"17","author":"Ponticelli","year":"2018","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib109","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.2015.318","article-title":"Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis","volume":"89","author":"Rathi","year":"2016","journal-title":"Kidney Int"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105785_bib110","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.32131","article-title":"Mycophenolate mofetil and new-onset systemic lupus erythematosus: a randomized clinical trial","volume":"7","author":"You","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib111","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S2665-9913(23)00320-X","article-title":"Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial","volume":"6","author":"Chakravarty","year":"2024","journal-title":"Lancet Rheumatol"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib112","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kead576","article-title":"Effect of antimalarials on clinical outcomes in lupus nephritis","volume":"63","author":"Pe\u00f1a-Vizcarra","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib113","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1136\/annrheumdis-2021-221295","article-title":"Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort","volume":"81","author":"Almeida-Brasil","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"14","key":"10.1016\/j.ebiom.2025.105785_bib114","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1001\/jama.2022.13591","article-title":"Hydroxychloroquine dose per ophthalmology guidelines and the risk of systemic lupus erythematosus flares","volume":"328","author":"Jorge","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib115","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/ard-2022-222486","article-title":"Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up","volume":"81","author":"Fu","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib116","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2022-222167","article-title":"Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis","volume":"81","author":"Hakroush","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib117","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/art.34359","article-title":"Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study","volume":"64","author":"Rovin","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib118","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ebiom.2025.105785_bib119","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2147\/DDDT.S195113","article-title":"Clinical efficacy and safety of rituximab in lupus nephritis","volume":"13","author":"Zhong","year":"2019","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.ebiom.2025.105785_bib120","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.38037","article-title":"Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study","volume":"65","author":"Mysler","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.ebiom.2025.105785_bib121","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1093\/rheumatology\/key042","article-title":"Ofatumumab for B cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab","volume":"57","author":"Masoud","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib122","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/ckj\/sfw022","article-title":"Ofatumumab treatment in lupus nephritis patients","volume":"9","author":"Haarhaus","year":"2016","journal-title":"Clin Kidney J"},{"issue":"22","key":"10.1016\/j.ebiom.2025.105785_bib123","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib124","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","article-title":"B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial","volume":"81","author":"Furie","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"15","key":"10.1016\/j.ebiom.2025.105785_bib125","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","article-title":"Efficacy and safety of obinutuzumab in active lupus nephritis","volume":"392","author":"Furie","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.41466","article-title":"Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis","volume":"73","author":"Atisha-Fregoso","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105785_bib127","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","article-title":"Two-year, randomized, controlled trial of belimumab in lupus nephritis","volume":"383","author":"Furie","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib128","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1053\/j.ajkd.2022.06.013","article-title":"Efficacy and safety of belimumab in patients with lupus nephritis: subgroup analyses of a phase 3 randomized trial in the East Asian population","volume":"81","author":"Yu","year":"2023","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105785_bib129","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/ndt\/gfad167","article-title":"Effect of belimumab on kidney-related outcomes in patients with lupus nephritis: post hoc subgroup analyses of the phase 3 BLISS-LN trial","volume":"38","author":"Anders","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib130","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/rheumatology\/kead253","article-title":"Belimumab and antimalarials combined against renal flares in patients treated for extra-renal systemic lupus erythematosus: results from 4 phase III clinical trials","volume":"63","author":"Gomez","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib131","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1002\/art.42620","article-title":"Comparative risks of infection with belimumab versus oral immunosuppressants in patients with nonrenal systemic lupus erythematosus","volume":"75","author":"Materne","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib132","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1136\/ard-2023-224152","article-title":"Sustained responses after anti-CD38 treatment with daratumumab in two patients with refractory systemic lupus erythematosus","volume":"82","author":"Alexander","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib133","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/s41591-023-02479-1","article-title":"Daratumumab monotherapy for refractory lupus nephritis","volume":"29","author":"Roccatello","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2025.105785_bib134","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.coi.2016.09.001","article-title":"T cells in systemic lupus erythematosus","volume":"43","author":"Su\u00e1rez-Fueyo","year":"2016","journal-title":"Curr Opin Immunol"},{"issue":"10289","key":"10.1016\/j.ebiom.2025.105785_bib135","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","article-title":"Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"397","author":"Rovin","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib136","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/art.42657","article-title":"Safety and efficacy of long-term voclosporin treatment for lupus nephritis in the phase 3 AURORA 2 clinical trial","volume":"76","author":"Saxena","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"10429","key":"10.1016\/j.ebiom.2025.105785_bib137","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/S0140-6736(23)02649-1","article-title":"Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial","volume":"403","author":"Cope","year":"2024","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib138","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.38790","article-title":"Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study","volume":"66","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib139","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/art.38260","article-title":"Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study","volume":"66","author":"Furie","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib140","doi-asserted-by":"crossref","first-page":"5397","DOI":"10.1093\/rheumatology\/keab381","article-title":"Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus","volume":"60","author":"Furie","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib142","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/art.42557","article-title":"Clinical and biomarker responses to BI 655064, an antagonistic anti-CD40 antibody, in patients with active lupus nephritis: a randomized, double-blind, placebo-controlled, phase II trial","volume":"75","author":"Jayne","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"11S","key":"10.1016\/j.ebiom.2025.105785_bib181","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1681\/ASN.20233411S1971a","article-title":"EQUALISE type B: clinical results of itolizumab, a novel Anti-CD6 therapy, in subjects with lupus nephritis","volume":"34","author":"Kalunian","year":"2023","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.ebiom.2025.105785_bib144","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-\u03b1 receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib145","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1912196","article-title":"Trial of anifrolumab in active systemic lupus erythematosus","volume":"382","author":"Morand","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib146","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","article-title":"Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial","volume":"1","author":"Furie","year":"2019","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib147","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/ard-2023-224762","article-title":"EULAR recommendations for the management of systemic lupus erythematosus: 2023 update","volume":"83","author":"Fanouriakis","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib148","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","article-title":"Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis","volume":"81","author":"Jayne","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib149","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.ekir.2023.08.033","article-title":"Clinical safety and efficacy of pegcetacoplan in a phase 2 study of patients with C3 glomerulopathy and other complement-mediated glomerular diseases","volume":"8","author":"Dixon","year":"2023","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib150","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s12882-021-02293-2","article-title":"Eculizumab therapy on a patient with co-existent lupus nephritis and C3 mutation-related atypical haemolytic uremic syndrome: a case report","volume":"22","author":"Kim","year":"2021","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.105785_bib151","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1681\/ASN.0000000534","article-title":"Efficacy and safety of ravulizumab in IgA nephropathy: a phase 2 randomized double-blind placebo-controlled trial","volume":"36","author":"Lafayette","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib152","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib153","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat Med"},{"issue":"10437","key":"10.1016\/j.ebiom.2025.105785_bib154","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2024.103692","article-title":"Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells","volume":"24","author":"He","year":"2025","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ebiom.2025.105785_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: a promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ebiom.2025.105785_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117212","article-title":"Recent advances in developing targeted protein degraders","volume":"284","author":"Cheng","year":"2025","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib158","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41421-024-00711-x","article-title":"PROTAC for Bruton's tyrosine kinase degradation alleviates inflammation in autoimmune diseases","volume":"10","author":"Zhu","year":"2024","journal-title":"Cell Discov"},{"issue":"11","key":"10.1016\/j.ebiom.2025.105785_bib159","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1056\/NEJMoa2106535","article-title":"Phase 2 trial of iberdomide in systemic lupus erythematosus","volume":"386","author":"Merrill","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib160","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1136\/annrheumdis-2022-222212","article-title":"Biological impact of iberdomide in patients with active systemic lupus erythematosus","volume":"81","author":"Lipsky","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib161","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jaad.2024.09.074","article-title":"Effect of iberdomide on cutaneous manifestations in systemic lupus erythematosus: a randomized phase 2 clinical trial","volume":"92","author":"Werth","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib162","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1158\/1535-7163.MCT-15-0667","article-title":"Activation of the constitutive androstane receptor increases the therapeutic index of CHOP in lymphoma treatment","volume":"15","author":"Hedrich","year":"2016","journal-title":"Mol Cancer Ther"},{"issue":"12","key":"10.1016\/j.ebiom.2025.105785_bib163","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.153868","article-title":"Targeting CAR and Nrf2 improves cyclophosphamide bioactivation while reducing doxorubicin-induced cardiotoxicity in triple-negative breast cancer treatment","volume":"7","author":"Stern","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib164","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.apsb.2016.07.016","article-title":"Insights into CYP2B6-mediated drug\u2013drug interactions","volume":"6","author":"Hedrich","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"10.1016\/j.ebiom.2025.105785_bib165","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/FPC.0000000000000506","article-title":"Genetic polymorphisms effect on cyclophosphamide's tolerability and clinical efficacy in Egyptian patients with lupus nephritis","volume":"33","author":"Abuelsoud","year":"2023","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.ebiom.2025.105785_bib166","doi-asserted-by":"crossref","first-page":"3655","DOI":"10.2147\/DDDT.S373487","article-title":"The efficacy of cyclophosphamide combined with prednisone in membranous nephropathy patients with different cytochrome P450 2B6 gene polymorphisms and analysis of factors influencing the efficacy","volume":"16","author":"Zhang","year":"2022","journal-title":"Drug Des Devel Ther"},{"issue":"5\u20136","key":"10.1016\/j.ebiom.2025.105785_bib167","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/14622416.2024.2344430","article-title":"Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review","volume":"25","author":"Yow","year":"2024","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.ebiom.2025.105785_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1443794","article-title":"In vitro mechanistic study on mycophenolate mofetil drug interactions: effect of prednisone, cyclosporine, and others","volume":"15","author":"Mao","year":"2024","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib169","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1681\/ASN.0000000608","article-title":"Nanotherapeutics in kidney disease: innovations, challenges, and future directions","volume":"36","author":"Roointan","year":"2025","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib170","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/s41581-024-00819-z","article-title":"Physiological principles underlying the kidney targeting of renal nanomedicines","volume":"20","author":"Huang","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1016\/j.ebiom.2025.105785_bib171","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","article-title":"Autoimmunity and organ damage in systemic lupus erythematosus","volume":"21","author":"Tsokos","year":"2020","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib172","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1186\/s13075-019-2038-0","article-title":"ALW peptide ameliorates lupus nephritis in MRL\/lpr mice","volume":"21","author":"Wang","year":"2019","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.ebiom.2025.105785_bib173","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/cei.12734","article-title":"A peptide mimic blocks the cross-reaction of anti-DNA antibodies with glomerular antigens","volume":"183","author":"Xia","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ebiom.2025.105785_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103205","article-title":"Anti-DNA antibody-targeted D-peptide nanoparticles ameliorate lupus nephritis in MRL\/lpr mice","volume":"145","author":"Wang","year":"2024","journal-title":"J Autoimmun"},{"issue":"24","key":"10.1016\/j.ebiom.2025.105785_bib175","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abb3900","article-title":"A highly potent lymphatic system-targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus","volume":"6","author":"Ganugula","year":"2020","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.ebiom.2025.105785_bib176","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s12951-021-00857-w","article-title":"Glycol chitosan-based tacrolimus-loaded nanomicelle therapy ameliorates lupus nephritis","volume":"19","author":"Kim","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.ebiom.2025.105785_bib177","article-title":"Dexamethasone prodrug nanomedicine (ZSJ-0228) treatment significantly reduces lupus nephritis in mice without measurable side effects \u2014 a 5-month study","volume":"31","author":"Zhao","year":"2021","journal-title":"Nanomedicine"},{"issue":"10","key":"10.1016\/j.ebiom.2025.105785_bib178","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/s41584-020-0480-7","article-title":"New insights into the role of antinuclear antibodies in systemic lupus erythematosus","volume":"16","author":"Pisetsky","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.ebiom.2025.105785_bib179","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201138","article-title":"Autoantibody-mediated impairment of DNASE1L3 activity in sporadic systemic lupus erythematosus","volume":"218","author":"Hartl","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.ebiom.2025.105785_bib180","first-page":"330","article-title":"Dexamethasone loaded DNA scavenger nanogel for systemic lupus erythematosus treatment","volume":"43","author":"Zhu","year":"2025","journal-title":"Bioact Mater"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425002294?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425002294?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:14:38Z","timestamp":1752614078000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425002294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":179,"alternative-id":["S2352396425002294"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105785","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in precision medicine for lupus nephritis: biomarker- and AI-driven diagnosis and treatment response prediction and targeted therapies","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.105785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105785"}}